^
    oncoReveal™ Nexus assesses key driver genes for both hematological and solid tumor malignancies in one multiplex reaction. The assay has a fully automatable workflow that can be performed by any clinical laboratory, batching up to eighty-one patient samples in a single Illumina MiSeq™ sequencing run, using as little as 2.5 ng DNA per patient sample. With a sample-to-report time within 2-3 days after DNA isolation, a laboratory deploying this panel will be able to quickly assess key driver alterations prior to initiating the laboratory process for comprehensive genomic profiling (CGP), enabling more rapid time-to-treatment and laboratory cost savings.
    Cancer:
    Hematological Malignancies, Solid Tumor
    Method:
    Next-Generation Sequencing (NGS)